Norbert Kraut

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 8

Top Topics

Acute Myeloid Leukemia

Structural Basis

Antiretroviral Therapy

Top Venues

Cancer discovery

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Venu Thatikonda, Hengyu Lu, Sabine Jurado, Kaja Kostyrko, Christopher A Bristow, Christoph Albrecht, Donát Alpár, Heribert Arnhof, Oliver Bergner, Karin Bosch, Ningping Feng, Sisi Gao, Daniel Gerlach, Michael Gmachl, Melanie Hinkel, Simone Lieb, Astrid Jeschko, Annette A Machado, Thomas Madensky, Ethan D Marszalek, Mikhila Mahendra, Gabriella Melo-Zainzinger, Jessica M Molkentine, Philipp A Jaeger, David H Peng, Robyn L Schenk, Alexey Sorokin, Sandra Strauss, Francesca Trapani, Edmund S Kopetz, Christopher P Vellano, Mark Petronczki, Norbert Kraut, Timothy P Heffernan, Joseph R Marszalek, Mark Pearson, Irene C Waizenegger, Marco H Hofmann
Co-targeting SOS1 enhances the antitumor effects of KRAS G12C inhibitors by addressing intrinsic and acquired resistance. Nature cancer (2024)
Venu Thatikonda, Hengyu Lu, Sabine Jurado, Kaja Kostyrko, Christopher A Bristow, Christoph Albrecht, Donát Alpár, Heribert Arnhof, Oliver Bergner, Karin Bosch, Ningping Feng, Sisi Gao, Daniel Gerlach, Michael Gmachl, Melanie Hinkel, Simone Lieb, Astrid Jeschko, Annette A Machado, Thomas Madensky, Ethan D Marszalek, Mikhila Mahendra, Gabriella Melo-Zainzinger, Jessica M Molkentine, Philipp A Jaeger, David H Peng, Robyn L Schenk, Alexey Sorokin, Sandra Strauss, Francesca Trapani, Edmund S Kopetz, Christopher P Vellano, Mark Petronczki, Norbert Kraut, Timothy P Heffernan, Joseph R Marszalek, Mark Pearson, Irene C Waizenegger, Marco H Hofmann
Co-targeting SOS1 enhances the antitumor effects of KRAS G12C inhibitors by addressing intrinsic and acquired resistance. Nature cancer (2024)
Andreas Gollner, Dorothea Rudolph, Ulrike Weyer-Czernilofsky, Rosa Baumgartinger, Peter Jung, Harald Weinstabl, Juergen Ramharter, Rolf Grempler, Jens Quant, Joerg Rinnenthal, Alejandro Pérez Pitarch, Bojana Golubovic, Daniel Gerlach, Gerd Bader, Kristiane Wetzel, Sebastian Otto, Christian Mandl, Guido Boehmelt, Darryl B McConnell, Norbert Kraut, Patrizia Sini
Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2-p53 Antagonist Suitable for Intermittent Dose Schedules. Molecular cancer therapeutics (2024)
Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski, Gintautas Vainorius, Neil Gibson, Irene C Waizenegger, Daniel Gerlach, Martin Augsten, Fiona Spreitzer, Yukina Shirai, Masachika Ikegami, Sylvia Tilandyova, Dirk Scharn, Mark A Pearson, Johannes Popow, Anna C Obenauf, Noboru Yamamoto, Shunsuke Kondo, Frans L Opdam, Annemarie Bruining, Shinji Kohsaka, Norbert Kraut, John Victor Heymach, Flavio Solca, Ralph A Neumuller
Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers. Cancer discovery (2024)
Dongsung Kim, Lorenz Herdeis, Dorothea Rudolph, Yulei Zhao, Jark Böttcher, Alberto Vides, Carlos I Ayala-Santos, Yasin Pourfarjam, Antonio Cuevas-Navarro, Jenny Y Xue, Andreas Mantoulidis, Joachim Bröker, Tobias Wunberg, Otmar Schaaf, Johannes Popow, Bernhard Wolkerstorfer, Katrin Gabriele Kropatsch, Rui Qu, Elisa de Stanchina, Ben Sang, Chuanchuan Li, Darryl B McConnell, Norbert Kraut, Piro Lito
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature (2023)
Marco H Hofmann, Daniel Gerlach, Sandra Misale, Mark Petronczki, Norbert Kraut
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. Cancer discovery 12 (4) (2022)
Marco H Hofmann, Michael Gmachl, Juergen Ramharter, Fabio Savarese, Daniel Gerlach, Joseph R Marszalek, Michael P Sanderson, Dirk Kessler, Francesca Trapani, Heribert Arnhof, Klaus Rumpel, Dana-Adriana Botesteanu, Peter Ettmayer, Thomas Gerstberger, Christiane Kofink, Tobias Wunberg, Andreas Zoephel, Szu-Chin Fu, Jessica L F Teh, Jark Böttcher, Nikolai Pototschnig, Franziska Schachinger, Katharina Schipany, Simone Lieb, Christopher P Vellano, Jonathan C O'Connell, Rachel L Mendes, Jurgen Moll, Mark Petronczki, Timothy P Heffernan, Mark Pearson, Darryl B McConnell, Norbert Kraut
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. Cancer discovery 11 (1) (2020)
Juan Manuel García-Martínez, Shirley Wang, Cordula Weishaeupl, Andreas Wernitznig, Paolo Chetta, Catarina Pinto, Jason Ho, Darrin Dutcher, Philip N Gorman, Rachel Kroe-Barrett, Joerg Rinnenthal, Craig Giragossian, Maria Antonietta Impagnatiello, Iñigo Tirapu, Frank Hilberg, Norbert Kraut, Mark Pearson, Klaus Peter Kuenkele
Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist. Molecular cancer therapeutics 20 (1) (2020)